ClinicalTrials.gg
CompletedNCT07001319Updated May 11, 2026

Study of GS-3242 in Participants With HIV-1; Substudy-05

A Phase 1 interventional study of GS-3242 and BVY in HIV-1-infection, sponsored by Gilead Sciences. Completed at 28 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH).

Substudy GS-US-544-5905-05 is to learn more about the study drug GS-3242 in PWH.

Read the detailed description

To refer master study protocol (GS-US-544-5905), refer to NCT05585307 on https://clinicaltrials.gov/

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

All Substudies:

  • Plasma -1 (HIV-1) ribonucleic acid (RNA) ≥ 5000 copies/mL but ≤ 400,000 copies/mL at screening.
  • Cluster of differentiation 4 (CD4) cell count > 200 cells/mm\^3 at screening.
  • Antiretroviral (ARV) treatment-naive or treatment-experienced but naive to the ARV drug class being investigated in the given substudy and have not received any ARV within 12 weeks of screening, including medications received for pre-exposure prophylaxis (PrEP) or postexposure prophylaxis (PEP) (note that current or prior receipt of long acting (LA) parenteral ARVs such as monoclonal antibodies (mAbs) targeting HIV-1, injectable cabotegravir (CAB), injectable rilpivirine (RPV) or injectable Lenacapavir (LEN) is exclusionary).
  • Have adequate renal function (estimated (eGFR) ≥ 70 mL/min/1.73 m\^2)
  • No abnormalities in (ECG) at screening.

Substudy-05:

  • Willing to initiate BVY provided by the sponsor, or an alternative SOC ART regimen selected by the investigator on Day 11 or upon ET.
  • Participants must also be willing to comply with meal requirements on dosing days.

Key Exclusion Criteria:

All Substudies:

  • Known historical genotypic or phenotypic resistance to 4 major ARV classes (nucleoside reverse transcriptase inhibitor (NRTI), nonnucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI), integrase strand-transfer inhibitor (INSTI)).
  • History of an AIDS-defining condition including present at the time of screening.
  • Active, serious infections (other than HIV-1) requiring therapy and including active tuberculosis infection \< 30 days prior to randomization.
  • History of or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, or variceal bleeding).
  • Any other serious or active clinical condition or prior therapy that, in the opinion of the investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements.
  • virus (HCV) antibody positive and detectable HCV RNA.
  • Chronic virus (HBV) infection, as determined by either:

    • 1. Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV core antibody status, at the screening visit, or
    • 2. Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the screening visit.
  • Hepatic transaminases ( (AST) or alanine aminotransferase (ALT)) > 5 x (ULN).
  • Current alcohol or substance use judged by the investigator to potentially interfere with individual study compliance.
  • Positive serum pregnancy test at screening or a positive pregnancy test prior to Day 1.
  • Individuals with plan to breastfeed during the study period including the protocol-defined follow-up period.
  • Requirement for ongoing therapy with or prior use of any prohibited medications listed in the protocol. Any prescription medications or over the counter medications, including herbal products, within 28 days prior to start of study drug dosing must be reviewed and approved by the sponsor, with the exception of vitamins and/or acetaminophen and/or ibuprofen.
  • Any current or prior receipt of LA parenteral ARVs such as mAbs targeting HIV-1, injectable CAB, or injectable RPV, or injectable LEN, for treatment or prophylaxis (PrEP, PEP).

Substudy-05:

  • Requirement for ongoing therapy with any prohibited medication.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Cohort 1: Single Dose of GS-3242

    Participants in cohort 1 will receive single dose of GS-3242 450 mg on Days 1 and 2 in the fasted condition. After assessments on Day 11 or upon early termination (ET), the participants initiate a regimen of bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) (BVY), or an alternative standard of care (SOC) antiretroviral (ART) regimen (example INSTI + NRTIs: dolutegravir (DTG)/abacavir (ABC)/3TC or DTG/3TC) up to Day 39. Following the completion of Cohort 1, additional cohorts may be opened for enrollment if further data are needed. Doses of GS-3242 will be based on safety and pharmacokinetic (PK) data from ongoing Phase 1a studies.

    Drug: GS-3242 · Drug: BVY · Drug: Standard of Care

Interventions

  • Administered orally

  • DrugBVY

    Administered orally

    Also known as: Biktarvy®

  • DrugStandard of Care

    Antiretroviral therapy, administered orally Non-NNRTIs, examples: ABC/ DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical Placebo Data

    Time frame: Baseline, Day 11

Secondary outcomes

  1. Change From Baseline in Plasma HIV-1 RNA (log10 Copies/mL) at Day 8 Relative to Historical Placebo Data

    Time frame: Baseline, Day 8

  2. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: First dose up to Day 39

  3. Percentage of Participants With Graded Laboratory Abnormalities

    Time frame: First dose up to Day 39

  4. Pharmacokinetic (PK) Parameter: Cmax of GS-3242

    Cmax is defined as the maximum observed concentration of drug.

    Time frame: Day 1 Predose up to Day 11

  5. PK Parameter: AUC of GS-3242

    AUC is defined as the area under the concentration versus time curve (AUC).

    Time frame: Day 1 Predose up to Day 11

  6. PK Parameter: Ct of GS-3242

    Ct is defined as the concentration at specified time "t".

    Time frame: Any day between Day 1 Predose up to Day 11

  7. Correlation Between Ct and/ or AUC versus the Change in Plasma HIV-1 RNA (Log10 Copies/mL) from Day 1 Through Day 11

    Time frame: Day 1 up to Day 11

  8. Percentage of Participants at Any Measurement Achieving HIV-1 RNA < 50 Copies/mL by Day 11 at Each Dose Level

    Time frame: Up to Day 11

  9. Percentage of Participants With Emergence of Viral Resistance to the ARV Class of the Given Drug (GS-3242)

    Time frame: Up to Day 11

07

Study locations

28 sites
  • Franco Felizarta, MD
    Bakersfield, California 93301, United States
  • Ruane Clinical Research Group, Inc
    Los Angeles, California 90036, United States
  • Mills Clinical Research
    Los Angeles, California 90069, United States
  • Quest Clinical Research
    San Francisco, California 94115, United States
  • Washington Health Institute
    Washington D.C., District of Columbia 20017, United States
  • Midland Florida Clinical Research Center, LLC
    DeLand, Florida 32720, United States
  • AIDS Healthcare Foundation - Northpoint
    Fort Lauderdale, Florida 33308, United States
  • Midway Immunology & Research Center, LLC
    Ft. Pierce, Florida 34982, United States
  • BLISS Health
    Orlando, Florida 32803, United States
  • Orlando Immunology Center, PA
    Orlando, Florida 32803, United States
  • Triple O Research Institute, P.A.
    West Palm Beach, Florida 33407, United States
  • Chatham County Health Department
    Savannah, Georgia 31401, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • Be Well Medical Center
    Berkley, Michigan 48072, United States
  • KC CARE Health Center
    Kansas City, Missouri 64111, United States
  • University of Cincinnati College of Medicine
    Cincinnati, Ohio 45267, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • Prism Health North Texas
    Dallas, Texas 75208, United States
  • North Texas Infectious Diseases Consultant's, P.A.
    Dallas, Texas 75246, United States
  • AXCES Research Group, LLC
    El Paso, Texas 79902, United States
  • AXCES Research Group, LLC
    Salt Lake City, Utah 84102, United States
  • ProcliniQ Investigación Clínica S.A. de C.V
    Mexico City, 6170, Mexico
  • Institute of HIV Research and Innovation (IHRI)
    Bangkok, 10330, Thailand
  • Faculty of Medicine Ramathibodi Hospital, Mahidol University
    Bangkok, 10400, Thailand
  • Faculty of Medicine Siriraj Hospital, Mahidol University
    Bangkok, 10700, Thailand
  • Srinagarind Hospital, Faculty of Medicine, Khon Kaen University
    Khon Kaen, 40002, Thailand
  • Bamrasnaradura Infectious Diseases Institute
    Nonthaburi, 11000, Thailand
  • The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT),Thai Red Cross AIDS and Infectious Disease Research Center
    Pathumwan, 10330, Thailand
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Mar 2026, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 3, 2025
StartActual
May 29, 2025
Primary completionActual
Mar 3, 2026
CompletionActual
Apr 16, 2026
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07001319
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
May 29, 2025
Primary completion
Mar 3, 2026
Completion
Apr 16, 2026
Last update
May 11, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GS-3242

Start the discussion